Loading...
Market
What will be the outcome of Phase 3 clinical trials for Liraglutide (Victoza) in Alzheimer's treatment by end of 2025?
2
Resolution / Starting Odds
Positive results • 25%
Negative results • 25%
Mixed results • 25%
Trial discontinued • 25%
Official trial results published by Novo Nordisk or in peer-reviewed journals
Story
Novo Nordisk's GLP-1 Drug Liraglutide (Victoza) Shows Potential in Slowing Alzheimer's Progression
Jul 30, 2024, 11:14 AM
Novo Nordisk's older GLP-1 drug, liraglutide, commonly used for managing diabetes and weight loss, appears to slow cognitive decline in Alzheimer's patients. According to Phase 2b clinical trial data presented at the Alzheimer's Association International Conference 2024, the drug may protect the brain and slow disease progression. The study, published on Tuesday, showed that liraglutide, known commercially as Victoza, yielded mixed results in a small mid-stage study but indicated a potential to slow the loss of brain volume in people with mild Alzheimer's disease.
View original story
Similar markets
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial not completed • 25%
Statistically significant improvement • 25%
No significant difference • 25%
Worse outcomes • 25%
Trial terminated early • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Not started • 25%
Yes • 50%
No • 50%
Successful with significant efficacy • 25%
Successful with moderate efficacy • 25%
Successful with minimal efficacy • 25%
Unsuccessful • 25%